KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $2.6 million.

  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) fell 3.90% to $641,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 105.38%. This contributed to the annual value of $2.6 million for FY2024, which is 24.21% up from last year.
  • As of FY2024, Xenon Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.6 million, which was up 24.21% from $2.1 million recorded in FY2023.
  • Xenon Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $2.6 million during FY2024, with a 5-year trough of $644,000 in FY2020.
  • In the last 3 years, Xenon Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $2.1 million in 2023 and averaged $2.0 million.
  • Data for Xenon Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY spiked of 55.08% (in 2022) over the last 5 years.
  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $644,000 in 2020, then soared by 40.68% to $906,000 in 2021, then surged by 55.08% to $1.4 million in 2022, then spiked by 46.69% to $2.1 million in 2023, then rose by 24.21% to $2.6 million in 2024.